



ADAP Advocacy  
PO Box 846  
Nags Head, NC 27959

[adapadvocacy.org](http://adapadvocacy.org)

**Board of Directors:**

**Chair**  
Jen Laws  
Slidell, LA

**Secretary**  
Guy Anthony  
Brooklyn, NY

**Treasurer**  
Wanda Brendle-Moss, R.N.  
Winston-Salem, NC

Robert "Bobby" Dorsey, Esq.  
Washington, DC

Eric Flowers  
Oakland, CA

Lyne Fortin, B.Pharm, MBA  
Montreal, Canada

Hilary M. Hansen  
Washington, DC

Lisa Johnson-Lett  
Birmingham, AL

Theresa Nowlin  
Dorchester, MA

Shabbir Imber Safdar  
San Francisco, CA

Jennifer Vaughan  
Watsonville, CA

**CEO**  
Brandon M. Macsata  
Washington, D.C.

**Directors Emeritus:**  
Michelle Anderson  
William Arnold – *in memoriam*  
John D. Kemp, Esq.  
Gary Rose – *in memoriam*  
Joyce Turner Keller  
Rani Whitfield, M.D.

## ADAP Advocacy Unveils Survey on Long-Acting Injectables Treatment

### *Survey Seeks Patient Perspectives on Long-Acting Injectables Treatment from People Living with HIV*

For Immediate Release:  
November 20, 2023

Media Contact:  
[info@adapadvocacy.org](mailto:info@adapadvocacy.org)

WASHINGTON, D.C. – ADAP Advocacy today, as part of its Long-Acting Injectables (LAIs) Project, launched an [online survey](#) to gain better patient perspectives from people living with HIV about approved LAIs medications for the treatment of HIV/AIDS. The online survey is open to people who are **HIV-Positive** and residing in the **United States** and its Territories.

LAIs are prescription medications designed to either prevent the transmission of HIV or treat HIV over an extended period. These medications can be used to replace daily oral medications. But anecdotal evidence suggests access barriers remain.

“Obstacles and operational barriers to timely access of new agents, especially injectables, have increased with the advent of newer injectable therapies” **summarized Riley Johnson, Project Manager of the ADAP Advocacy’s Long-Acting Injectables Project.** “The barriers that commonly occur hinder equitable access for people living with HIV, especially those relying on publicly financed programs such as State AIDS Drug Assistance Programs or Medicaid, but also for people on private insurance. Our survey provides patients an opportunity to share their experiences.”

The U.S. Food & Drug Administration (FDA) recently approved newer long-acting injectable therapies, including ViiV Healthcare’s [Cabenuva](#) (cabotegravir and rilpivirine, injectable formulation), and Gilead Sciences’ [Sunlenca](#) (lenacapavir). These therapies complement older LAIs already on the market and pave the way for products in development.

People living with HIV can take the survey, here: <https://cutt.ly/LAI-Survey>.

ADAP Advocacy’s Long-Acting Injectables Project is made possible with support from Gilead Sciences, Merck, and ViiV Healthcare.

To learn more about ADAP Advocacy, AIDS Drug Assistance Programs, or its Long-Acting Injectables Project, please email [info@adapadvocacy.org](mailto:info@adapadvocacy.org).

#####

**About ADAP Advocacy:** ADAP Advocacy’s mission is to promote and enhance the AIDS Drug Assistance Programs (ADAPs) and improves access to care for persons living with HIV/AIDS. ADAP Advocacy works with advocates, community, health care, government, patients, pharmaceutical companies, and other stakeholders to raise awareness, offer patient educational programs, and foster greater community collaboration.